Project Grant K23HL183763
Award Date 8/20/26
Completion Date 5/31/31
Dollars Obligated $187K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute awarded New York University $847,163 on August 13, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement the Community-to-Clinic Implementation Program to Control Hypertension in Barbershops (CLIP HTN). The award funds a research initiative to test whether community health worker-delivered hypertension screening and linkage services delivered through barbershops improve blood pressure control and linkage to...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded $338,934 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, on September 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for a K01 mentored career development award titled "Start Strong: A Mixed Methods Study to Inform Initial Antihypertensive Prescribing and a Patient-Self Titration Intervention to Improve Blood Pressure Control, Safety, and Reduce Cardiovascular...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $173,929 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a Mentored Research Scientist Development Award (K01) for Dr. Goulding's training and research in cardiovascular disease prevention and management in youth with hypertension. The award funds training, mentorship, and research development for Dr. Goulding, an assistant professor and behavioral...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $754,413 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized controlled trial of remote blood pressure monitoring, pharmacist-led telehealth medication management, and automated text reminders integrated into an emergency department transitional care clinic model for hypertensive patients. The trial, titled REMAP-BP (Remote Blood Pressure...
- The National Heart Lung and Blood Institute awarded New York University $510,538 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid effectiveness-implementation study integrating the HEARTS package—a World Health Organization–recommended strategy comprising healthy lifestyle counseling, evidence-based treatment protocols, access to medicines, risk-based care, task-sharing, and systems monitoring—into primary healthcare centers in Nigeria...
- The National Heart, Lung, and Blood Institute awarded New York University's Long Island School of Medicine $201,744 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support Dr. Arabadjian's progression from mentored researcher to independent investigator focused on cardiovascular health promotion among socially vulnerable mothers of young children. The award funds a career development program combining structured training in clinical trial design,...
- Federal Grant Award Summary New York University School of Medicine received a $248,999 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 14, 2025, with completion scheduled for June 30, 2028. This K99/R00 Pathway to Independence Award supports the development and evaluation of time-restricted eating (TRE) as a weight loss maintenance strategy. The award funds a pilot randomized...